Written and maintained by CASRAI Editorial Board
Last updated
Digital therapeutics (DTx) are evidence-based, clinically evaluated software interventions designed to prevent, manage, or treat a specific medical disease or disorder. Unlike general consumer wellness applications or passive medication reminders, Prescription Digital Therapeutics (PDTs) deliver active therapeutic mechanisms of action—such as computerized cognitive behavioral therapy (cCBT), neuro-behavioral biofeedback, or closed-loop physiological titration—validated in randomized controlled trials (RCTs) and regulated as Software as a Medical Device (SaMD).
What Is Digital Therapeutics and How Is It Used in Clinical Research and Healthcare?
As defined by the Digital Therapeutics Alliance (DTA) and the International Organization for Standardization in ISO/TR 11147:2023 (Health informatics — Personalized digital health — Digital therapeutics health software systems) (https://www.iso.org/standard/83767.html), a digital therapeutic is health software intended to treat or alleviate a disease, disorder, condition, or injury by generating and delivering a medical intervention that has a demonstrable positive therapeutic impact on a patient’s health.
In clinical practice and translational research, DTx products are stratified into two primary operational categories:
- Prescription Digital Therapeutics (PDTs): Clinician-prescribed software devices cleared or authorized by regulatory authorities (such as the FDA CDRH) for specific diagnostic indications—including substance use disorder, chronic insomnia, attention-deficit/hyperactivity disorder (ADHD), major depressive disorder, fibromyalgia, and irritable bowel syndrome.
- Non-Prescription / Over-the-Counter (OTC) Digital Therapeutics: Clinically validated software interventions deployed through employer health plans, chronic disease management programs, or integrated delivery networks without an individual prescription requirement.
Methodological Rigor in DTx Clinical Trials: Digital Sham Controls
Because patient interaction with a mobile or tablet interface can induce a potent “digital placebo effect,” clinical trials evaluating digital therapeutics require specialized experimental design:
- Active Digital Sham Comparators: Rather than comparing a DTx solely against a waitlist or treatment-as-usual (TAU) unblinded control arm, pivotal FDA registrational trials employ a double-blind digital sham control—an application with an identical visual user interface, notification schedule, and time-on-task engagement requirement, but stripped of the active therapeutic algorithm (for example, neutral trivia or non-adaptive attention tasks instead of cognitive restructuring or dual-task motor-cognitive training).
- Engagement-Dose-Response Modeling: Trial biostatisticians capture granular telemetry—session completion rates, module dwell time, and interactive task accuracy—to model Intention-to-Treat (ITT) and Per-Protocol dose-response relationships while accounting for digital attrition.
- Software Lifecycle Freezing and Version Traceability: Under IEC 62304 and Good Clinical Practice (ICH E6), the therapeutic algorithm version must remain locked or strictly version-controlled throughout the pivotal RCT.
What Standards or Regulatory Requirements Govern Digital Therapeutics?
Globally, regulatory agencies evaluate digital therapeutics as Software as a Medical Device (SaMD), while pioneering reimbursement authorities have created dedicated statutory fast-track frameworks:
| Jurisdiction / Framework | Regulatory / Coverage Pathway | Evidence & Technical Standards Required |
|---|---|---|
| United States — FDA CDRH | Class II De Novo Classification or 510(k) Premarket Notification (under 21 CFR Part 882 / Part 890 product codes such as PWE, QFT, QMY). |
Pivotal RCT clinical data, IEC 62304 software lifecycle docs, ISO 14971 risk management, and cybersecurity SBOM controls under FD&C Act § 524B. |
| United States — CMS Medicare | HCPCS Level II Code A9291 and CY 2025 Physician Fee Schedule Codes G0552–G0554; plus Remote Therapeutic Monitoring (RTM) CPT 98975–98981. |
A9291 covers FDA-cleared prescription digital behavioral therapy; G0552 covers supply of FDA-cleared Digital Mental Health Treatment (DMHT) devices incident to professional behavioral health care. |
| Germany — BfArM DiGA Fast-Track | Digital Healthcare Act (DVG — Digitale Gesundheitsanwendungen) administered by BfArM (https://diga.bfarm.de/). | CE-marked Class I or IIa MDR device, BSI IT security/interoperability audit, and comparative clinical study demonstrating a positive healthcare effect (medical benefit or structural/procedural improvement) for statutory health insurance (GKV) reimbursement (12-month provisional or permanent listing). |
| United Kingdom — NICE EVA | NICE Early Value Assessment (EVA) for HealthTech & DTAC (Digital Technology Assessment Criteria). | Conditional NHS adoption while real-world clinical and cost-effectiveness evidence is generated alongside DCB0129 clinical safety compliance. |
How Does Digital Therapeutics Integrate with EHR and Health Informatics Workflows?
To prevent clinician workflow fragmentation, enterprise DTx platforms integrate directly into hospital and ambulatory EHR integration pipelines using HL7 FHIR R4 and SMART on FHIR standards:
- EHR Order Placement (`ServiceRequest` / `MedicationRequest`): Clinicians prescribe a PDT from within Epic or Oracle Health order sets. The order is transmitted to the DTx specialty pharmacy or fulfillment hub via HL7 FHIR
ServiceRequestor NCPDP SCRIPT transactions, which automatically provisions a patient activation access code via SMS/email. - Adherence and Digital Biomarker Write-Back (`Observation`): As the patient completes therapeutic modules at home, the DTx platform transmits structured adherence metrics (sessions completed, days active in 30-day window for RTM billing) and validated patient-reported outcome measures (such as PHQ-9 or GAD-7 scores) back to the EHR as LOINC-coded FHIR
Observationresources. - Clinician Dashboard Launch via SMART on FHIR: Treating clinicians review longitudinal therapeutic progress curves and RTM time-tracking logs directly inside the EHR chart via an embedded SMART on FHIR iframe without logging into an external vendor portal.
Frequently Asked Questions
What is digital therapeutics and how is it used in clinical research and healthcare?
Digital therapeutics (DTx) are clinically validated software-as-a-medical-device (SaMD) interventions that deliver active therapeutic mechanisms—such as computerized cognitive behavioral therapy or neuromuscular biofeedback—to treat or manage medical conditions, evaluated in clinical research through double-blind sham-controlled randomized trials.
What standards or regulatory requirements govern digital therapeutics?
In the United States, Prescription Digital Therapeutics are regulated by the FDA as Class II medical devices via the De Novo or 510(k) pathways (requiring IEC 62304 and ISO 14971 compliance) and billed under HCPCS codes A9291, G0552–G0554, or RTM CPT codes 98975–98981, while in Germany they are governed and reimbursed under BfArM’s statutory DiGA Fast-Track framework.
How does digital therapeutics integrate with EHR and health informatics workflows?
Digital therapeutics integrate with EHRs using SMART on FHIR and HL7 FHIR R4 APIs—receiving clinician prescriptions via ServiceRequest or MedicationRequest, provisioning patient access tokens automatically, and writing module adherence and patient-reported outcome scores back into the chart as structured Observation resources.
